Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Direct KRAS Effector Pathways Involved in Cell Transformation & Lung Tumorigenesis . KRAS activates signaling downstream of the RAF, PI3K and RAL pathways, which have been firmly established as ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

The team demonstrated that tumor cells make new fat through the KRAS-MAPK pathway. "KRAS is the master regulator of pancreatic cancer, and new medicines are now in clinical trials to bring down ...

“ The RAMP 203 study is investigating the potential benefits of a more complete vertical blockade of the RAS pathway with the combination of avutometinib and sotorasib in KRAS G12C-mutant ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Quiver AI Summary ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Direct KRAS effector pathways involved in cell transformation & lung tumorigenesis RAF, PI3K and the RAL guanine exchange factor (RAL-GEF) were initially identified as essential components of RAS ...

BOSTON, May 08, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...